CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
APAC
CANADA

About Us

Conference

Partner With Us

  • Europe
    • US
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Biotech
    Cancer Immunotherapy
    Cell and Gene Therapy Companies
    Clinical Trial Management
    Drug Discovery and Development
    Genomics
    Therapeutics
    Women's Health
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    CDMO
    Clinical Laboratory Services
    CRO
    Microgravity R&D
    Supplements
  • Business Services
    Clinical Research Training
    Life Science Consulting
    Life Science Logistics
    Life Science Marketing
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

Drug Discovery and Development Europe

Top Antiviral Drug Development Platforms in Europe 2026

Antiviral drug development platforms help pharmaceutical researchers discover and evaluate treatments targeting viral infections. With a focus on compound screening, molecular analysis, therapeutic validation and development efficiency, they support more effective antiviral research and stronger drug discovery pipelines.

Solutions
ATB Antivirals Oy: Targeting Viral Infection at Its Source
ATB Antivirals Oy
Targeting Viral Infection at Its Source
Dr Preethy Paul, Co-founder and CEO
A promising antiviral treatment is only the beginning of drug development. Before pharmaceutical companies invest in costly, large-scale clinical trials, they need clear evidence that a treatment can work. Generating that evidence early helps biotechnology companies demonstrate the potential of their research and attract partners for further development.
Read more
State of Industry

Antiviral Drug Development Platforms in Europe: Advancing Rapid Therapeutic Innovation

Antiviral drug development platforms bring together innovative technology, scientific expertise and data-driven strategies to streamline and speed up the identification and creation of new antiviral drugs. The platforms are making research easier and faster, and enhancing the identification of drug candidates, which in return supports organisations to meet changing healthcare demands.

Read more
Deep Dive

How Antiviral Platforms Convert Mechanism into Clinical Proof

Antiviral development is difficult to evaluate because the scientific target can be compelling while the development path remains uncertain. Programs aimed at persistent infections face a different burden from products intended to block acute infection before it takes hold. Executives need to understand whether a platform has a defined biological rationale and whether its formulation suits the point of intervention. The development plan must also generate meaningful evidence early enough to support further investment.

Read more
Leadership Perspective
Integrating Novel Approaches for Safer Drug Development
Debiopharm
Integrating Novel Approaches for Safer Drug Development
Ulf Andersson, Head of Preclinical Safety and Translational Pharmacology

Ulf Andersson, the exceptional leader of Debiopharm’s preclinical safety and translational pharmacology teams, is at the forefront of integrating safety and efficacy in drug development. Formerly steering AstraZeneca’s safety science team in CVRM diseases, his wealth of experience spans oncology and antimicrobials. Ulf’s unique perspective, driven by a molecular approach, elevates risk assessment with quantitative precision. His commitment to advancing medicine through cutting-edge AI-driven models and prescient insights promises groundbreaking results in predicting toxicity and optimising drug combinations.

Read more

Antiviral Drug Development Platforms in Europe Info

Q1
What Do Antiviral Drug Development Platforms Include?
Antiviral drug development platforms bring together the work needed to move a treatment candidate from target identification toward clinical evaluation. This can include active-compound development, formulation design and preclinical testing. Depending on the therapeutic aim, a program may seek to prevent viral entry, disrupt replication, target viral proteins or limit infection in affected tissues. Top Antiviral Drug Development Platforms in Europe work across different stages of this pathway. Approaches may involve small-molecule compounds, biologically active substances, topical formulations and other drug delivery methods. The aim is to establish whether a candidate merits further testing.
Q2
Which Antiviral Drug Development Platform Received Recognition in Europe in 2026?
Life Sciences Review Europe recognized ATB Antivirals Oy as the Top Antiviral Drug Development Platform in Europe 2026. The Finnish biotechnology company is developing candidates for persistent human papillomavirus (HPV) infection and respiratory viral infections. Its portfolio addresses specific points in the course of infection through both therapeutic and preventive approaches, reflecting the range of work represented by Top Antiviral Drug Development Platforms in Europe.
Q3
Why Is Demand for Antiviral Drug Development Platforms Growing?
Viral infections differ in how they spread, persist and affect the body. Persistent infections may call for treatments that address underlying viral activity, while acute respiratory infections create interest in interventions that could prevent infection from becoming established. Top Antiviral Drug Development Platforms in Europe help turn scientific findings into candidates for systematic testing. Pharmaceutical and biotechnology partners need early evidence of biological activity, safety considerations and formulation feasibility before committing resources to clinical programs.
Q4
How Are Technology and Scientific Expertise Shaping Antiviral Drug Development?
Antiviral research examines where a treatment can interrupt viral activity. Top Antiviral Drug Development Platforms in Europe may use molecular targeting, combination approaches, specialized drug delivery and preclinical testing models to assess a candidate’s potential. Formulation must suit the intended treatment site. Topical products can deliver compounds to affected tissue, while nasal formulations may target respiratory mucosal surfaces. Teams must establish that the mechanism is credible and the delivery method suits its intended use. Laboratory and animal findings should not be confused with demonstrated clinical safety or efficacy.
Q5
What Should Pharmaceutical Partners Evaluate When Assessing Antiviral Development Platforms?
The scientific rationale is only one part of the assessment. Top Antiviral Drug Development Platforms in Europe should be evaluated on target selection, mechanism of action, formulation feasibility and relevant preclinical findings. Partners should also look at development timelines, regulatory needs, manufacturing readiness, and planned clinical studies. Having a clear path from preclinical validation to early human trials helps partners assess risk. Licensing deals and supporting research are important too.
Q6
What Distinguishes ATB Antivirals Oy’s Antiviral Development Approach?
ATB Antivirals Oy was recognized for its development portfolio. Its ATB 101 candidate targets HPV oncoproteins E6 and E7, and research is looking at how it causes protein degradation through a ubiquitin-mediated pathway. The compound has been tested in preclinical studies with naturally occurring lesions and animal models. Its second candidate, ATB 201, is a preventive nasal spray combining three repurposed, clinically used active ingredients with complementary actions involving viral entry, replication and local inflammation. The company has also demonstrated industrial-scale production and topical formulation of ATB 101. Both candidates are being advanced toward early clinical proof of concept before potential licensing partnerships.
Life Sciences Review Europe
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review Europe. All rights reserved.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesrevieweurope.com/a/antiviral-drug-development-platforms-in-europe